Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages

The advent of CAR T cells targeting CD19 or BCMA on B cell neoplasm demonstrated remarkable efficacy, but rapid relapses and primary refractoriness remains challenging. A leading cause of CAR T cell failure is their lack of expansion and limited persistence. Long-lived, self-renewing multipotent T m...

Descripción completa

Detalles Bibliográficos
Autores principales: Joedicke, Jara J., Großkinsky, Ulrich, Gerlach, Kerstin, Künkele, Annette, Höpken, Uta E., Rehm, Armin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791860/
https://www.ncbi.nlm.nih.gov/pubmed/35118163
http://dx.doi.org/10.1016/j.omtm.2021.12.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791860/
https://www.ncbi.nlm.nih.gov/pubmed/35118163
http://dx.doi.org/10.1016/j.omtm.2021.12.005

Ejemplares similares